Domača stranLGND • NASDAQ
add
Ligand Pharmaceuticals Inc
114,83 $
Pred odprtjem:(0,29 %)−0,33
114,50 $
Konec trgovanja: 10. mar., 04:05:28 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
116,00 $
Dnevni razpon
112,13 $ - 117,10 $
Letni razpon
67,72 $ - 129,90 $
Tržna kapitalizacija
2,17 mrd. USD
Povprečni obseg
94,34 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 42,81 mio. | 52,35 % |
Stroški poslovanja | 51,74 mio. | 21,41 % |
Čisti dohodek | −31,09 mio. | −270,93 % |
Čista dobičkovnost prihodkov | −72,62 | −212,21 % |
Earnings per share | 1,27 | −7,97 % |
EBITDA | 10,31 mio. | 85,57 % |
Efektivna davčna stopnja | 20,69 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 256,16 mio. | 50,41 % |
Skupna sredstva | 941,77 mio. | 19,63 % |
Skupne obveznosti | 111,34 mio. | 29,00 % |
Celoten lastniški kapital | 830,44 mio. | — |
Shares outstanding | 19,26 mio. | — |
Razmerje P/B | 2,67 | — |
Donosnost sredstev | 0,44 % | — |
Donosnost kapitala | 0,50 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −31,09 mio. | −270,93 % |
Denar iz dejavnosti | 28,47 mio. | 253,02 % |
Denar iz naložb | −38,62 mio. | −275,56 % |
Denar iz financiranja | 20,39 mio. | 283,59 % |
Neto sprememba denarnih sredstev | 8,69 mio. | 180,62 % |
Prost denarni tok | 43,18 mio. | 325,86 % |
Vizitka
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.
The company has been the subject of multiple regulatory investigations, negative shorts-seller reports and class action lawsuits amid allegations of securities fraud.
In 2018 its CEO was listed among the top five highest paid CEOs in San Diego. Wikipedia
Datum ustanovitve
sep. 1987
Spletno mesto
Zaposleni
68
